A long-acting blood pressure medication that also switches on a cellular sensor for fat storage and insulin handling. One morning dose covers a full day. Pooled analyses show modest gains in blood sugar handling, inflammatory signals, fat around the internal organs, and kidney protein leakage; whether these add years remains unclear. Harms: low pressure on standing, rising potassium, pregnancy injury. (Full Review)

Protocol

Standard hypertensive protocol

40 mg once daily

Titrated to 80 mg after 4 weeks if the target is not achieved; licensed range 20–80 mg. No additional reduction above 80 mg.

Conservative metabolic and longevity protocol

20 mg daily

Held there, or titrated to 40 mg only if pressure permits. Inferred from trial dosing, not validated at 20 mg for metabolic endpoints.

Best time of day

Morning

Standard, and what the pivotal trials used; separates the peak effect from the overnight pressure trough. With or without food.

Time to effect

Blood pressure

4–8 weeks

Pressure begins to fall within 3 hours of the first dose; steady state by day 5–7.

Insulin sensitivity

12–24 weeks

Insulin sensitivity and adiponectin changes were measured after 12–24 weeks of continuous use.

Visceral fat

24 weeks or longer

Six months is the earliest point at which the change is detectable.

Benefits

High: Sustained 24-hour blood pressure reduction; cardiovascular event protection in high-risk adults; improved insulin sensitivity relative to other agents in its class

Medium: Preferential reduction of visceral fat; reduction in circulating inflammatory markers; reduced urinary protein loss; improved endothelial function; reduced atrial fibrillation recurrence; improved blood fat profile

Low: Lower stroke, heart failure, and mortality rates versus other agents in its class; improvement in fatty liver markers; preservation of cognitive function; reduced migraine frequency

Speculative: Lifespan extension; antitumour and immune-modulating activity; enhanced mitochondrial biogenesis and exercise capacity

Contraindications

Pregnancy at any stage, and women actively attempting conception

Breastfeeding

Documented bilateral renal artery stenosis, or unilateral stenosis in a solitary functioning kidney

Biliary obstructive disorders, and hepatic impairment of Child-Pugh Class C severity

Prior angioedema attributed to any renin-angiotensin-acting drug

Serum potassium above 5.5 mEq/L before treatment

eGFR below 30 mL/min/1.73 m²

Concurrent aliskiren with diabetes or eGFR below 60 mL/min/1.73 m²

Symptomatic hypotension, or seated systolic pressure below 100 mmHg

Severe aortic or mitral stenosis, and NYHA Class IV heart failure

Acute decompensated heart failure, or myocardial infarction within 90 days

Known hereditary fructose intolerance

Key Interactions

ACE inhibitors (lisinopril, ramipril, enalapril, perindopril)

Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)

Potassium supplements and potassium-based salt substitutes (potassium chloride, potassium citrate, "low-sodium" salts)

Trimethoprim, including in co-trimoxazole

NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib, high-dose aspirin)

Lithium

Digoxin

Glucose-lowering drugs (insulin, metformin, sulfonylureas)

Warfarin

Blood-pressure-lowering supplements (dietary nitrate, citrulline, arginine, garlic, hibiscus, olive leaf, grape seed, magnesium, taurine, hawthorn, coenzyme Q10, high-dose omega-3)

Potassium-raising supplements and botanicals (potassium citrate or gluconate, noni juice, alfalfa, nettle, dandelion, horsetail)

Blood-pressure-raising supplements and stimulants (yohimbine, ephedra, synephrine, high-dose caffeine, licorice root)

Sauna, heat exposure, endurance training, fasting, and low-carbohydrate diets

Risk & Side Effects

High: Fetal toxicity; symptomatic hypotension and dizziness; hyperkalaemia; harm from combination with an ACE inhibitor

Medium: Decline in kidney filtration rate; back pain, sinusitis, and diarrhoea

Low: Angioedema; mild anaemia; rhabdomyolysis; hypoglycaemia in users on glucose-lowering therapy; cancer signal

Speculative: Nitrosamine impurities in generic supply; blunting of exercise training adaptations; long-term consequences of sustained PPAR-γ activation

Monitoring

Marker	Target	Why
Home blood pressure (7-day average)	110–120 / 70–78 mmHg	Primary efficacy endpoint
Orthostatic blood pressure drop	Under 10 mmHg systolic	Detects excessive dosing before syncope
Serum potassium	4.0–4.5 mEq/L	Primary safety marker; main dose-limiting risk
Serum creatinine and eGFR	eGFR above 90 mL/min/1.73 m²	Detects haemodynamic or structural kidney injury
Urine albumin-to-creatinine ratio	Under 10 mg/g	Tracks the kidney-protective effect
Fasting insulin	Under 5 µIU/mL	Core metabolic endpoint
HOMA-IR (calculated)	Under 1.0	Best summary of insulin resistance
Fasting glucose	75–85 mg/dL	Confirms direction of the insulin sensitivity change
HbA1c	4.8–5.4%	Confirms metabolic change over a 3-month window
hs-CRP	Under 0.5 mg/L	Tracks the inflammatory effect
Triglycerides	Under 80 mg/dL	Lipid component of the metabolic effect
Haemoglobin and haematocrit	Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women)	Detects mild suppression of red cell production
Uric acid	3.5–5.5 mg/dL	Baseline marker; unaffected, unlike losartan
ALT and AST	ALT under 20 U/L (men), under 17 U/L (women)	Monitors biliary elimination and fatty-liver effect
Serum sodium	137–142 mEq/L	Detects volume depletion and sodium over-restriction
Blood urea nitrogen	12–18 mg/dL	Distinguishes volume depletion from kidney injury
Visceral fat area or waist circumference	Waist under 94 cm (men), under 80 cm (women)	Tracks the fat-redistribution effect

Cadence: Potassium and creatinine at 1–2 weeks, at 4 weeks, and after every dose increase; the full panel at 3 months, at 6 months, and every 6–12 months thereafter once stable. Home blood pressure daily for 2 weeks, then twice weekly, with a 7-day average recalculated monthly. Body composition at 6 months.

Qualitative Assessment

Light-headedness on standing or after exercise: the earliest indicator that the dose exceeds what baseline pressure tolerates
Early-morning energy and clarity: new morning heaviness can indicate overnight pressure falling too low
Exercise tolerance and perceived effort at a fixed workload: deterioration may reflect excessive pressure reduction or reduced red cell production
Absence of dry cough: a defining advantage over ACE inhibitors; a new persistent cough warrants looking for another cause
Back discomfort, sinus congestion, or loose stools: the characteristic minor adverse effects of this drug
Sleep continuity and nocturnal urination frequency: can reflect altered overnight haemodynamics and fluid handling
Any swelling of lips, tongue, or face: prompts immediate cessation and urgent medical assessment, however mild

Telmisartan for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment